With the meteoric rise in demand for GLP-1 medications, hospital systems around the country are facing a myriad of questions ranging from coverage for their employees and negotiations with insurers to addressing access and affordability. 

Dr. Stephen Klasko sat down with Becker’s Healthcare Review VP Molly Gamble, to discuss what he says healthcare systems should be focusing on to harness the potential of these groundbreaking treatments and develop solutions that enhance equitable access. Click here to read the article.